Hints and tips:
...It sold the US rights to Nucynta, opioid-based pills and an oral solution, to California-based Depomed for just over $1bn. It stopped marketing Duragesic in 2008, though it still sells it....
...Johnson & Johnson sold its painkiller franchise to Depomed, a much smaller company, for $1bn in 2015. It has also offloaded its opium poppy processing business, as has GSK....
...The new system would probably be funded by the pharmaceutical groups that manufacture opioid medicines — such as Perdue Pharma, Endo and Depomed — which have been sharply criticised for fuelling the crisis...
...J&J, the largest company named in the litigation, has deep pockets, but it sold its opioid franchise in 2015 to Depomed, while Purdue does not disclose its financial results....
...The new offer values Depomed at about $2bn....
...Meanwhile, Depomed climbed 24.7 per cent to $5.50 after announcing late on Friday of positive results from trials of its neuropathic pain drug....
International Edition